Insilico Medicine

Insilico Medicine is a clinical-stage biotechnology company that leverages generative AI to discover and develop innovative drugs for various diseases, including cancer, fibrosis, and aging-related conditions. Their AI platforms utilize advanced machine learning techniques to discover novel drug targets and generate molecules with desired properties. The company aims to accelerate drug discovery and development through AI and automation.

Funding Round: Series E

Funding Amount: $110M

Date: 13-Mar-2025

Investors: Value Partners Group, industry- and technology-focused new investors, global existing backers

Markets: AI, Biotech, Drug Discovery

HQ: Cambridge, Massachusetts, United States

Founded: 2014

Website: http://www.insilico.com/

LinkedIn: https://www.linkedin.com/company/in-silico-medicine

Twitter: https://twitter.com/insilicomeds

Instagram:

Facebook: https://www.facebook.com/insilicomedicine